Federal Circuit Affirms Injunctions on Eylea Biosimilar Sales

The Federal Circuit left in place a pair of orders blocking two competitors of Regeneron Pharmaceuticals Inc. from marketing biosimilar versions of its blockbuster eye-disease drug Eylea in a Wednesday ruling.

The West Virginia federal judge who issued the injunctions correctly concluded the court had jurisdiction to consider the suit against South Korea-based Samsung Bioepis Co. even though the drug maker was working through a distributor to sell its product, the Federal Circuit ruled. The district court in June approved the preliminary injunctions, including one blocking Samsung Bioepis and another against Formycon AG that was separately affirmed Wednesday.

Specifically, the ...